James Glynn appointed to eBioscience, Inc. Board of Directors

eBioscience Corporation announced today that James Glynn has been appointed to its board of directors , effective April 15, 2008.

Mr. Glynn has over 34 years of combined financial, operating and director level experience, and is well known within the life sciences industry for his role in the growth and development of several biotechnology companies. Most notably, Mr. Glynn retired from Invitrogen Corporation (NASDAQ: IVGN) in 2003 where, during his tenure with the company, he held several operating roles including CFO, President and COO and CEO. During this time, Mr. Glynn led the company through several stages of growth including an IPO, numerous financings and several acquisitions including Novex, GIBCO Life Technologies, Research Genetics and Molecular Probes. Mr. Glynn, following his retirement from Invitrogen Corporation remained on the company’s board of directors until April 2006.

“We are very pleased to be adding someone of Jim’s reputation and experience to our board,” said Todd R. Nelson Ph.D., eBioscience’s Chief Executive Officer. “As an emerging global leader in the cellular analysis market, we are focused on growing our business operations through the development and commercialization of a diverse array of products, and also through the operational execution of several key strategic initiatives. In his role as director, Mr. Glynn will provide invaluable operating insight, financial advice and strategic guidance to ensure eBioscience remains a leader in the life sciences market place.” Brian Seed Ph.D., Chairman of the board of directors for eBioscience added “we look forward to tapping into Jim’s wealth of operating wisdom and the insights gleaned from his decades of senior management experience in the life science and related industries. Jim enjoys an enviable reputation among investors and professional fund managers for his business insight, strategic acumen, and proven ability to contribute guidance at the board level.”

Prior to joining Invitrogen Corporation in 1998 as the company’s CFO, Mr. Glynn served as CFO for Matrix Pharmaceutical, Inc. from 1995 – 1998 and as CFO for Mycogen Corporation from 1987 to 1995. Prior to that he was Vice President, Finance & Treasurer of Lubrizol Enterprises, Inc and an Audit manager for Price Waterhouse & Co. from 1974 to 1982.

Mr. Glynn currently serves as a director for Alphatec Spine, Inc; and American Specialty Health. eBioscience, headquartered in San Diego, California provides products and services that support academic and government research institutions and pharmaceutical and biotech companies worldwide. The company provides essential life science technologies for disease research and drug discovery. For more information, visit www.ebioscience.com.

CONTACT: eBioscience Corporation
Media Contact:
Noosheen Alaverdi, 858-642-2058 x132
nalaverdi@ebioscience.com

SOURCE: eBioscience Corporation

Back to News & Events